2436-18-2

Usage

Uses

Used in Pharmaceutical Industry:
7-Methoxyindole-3-acetonitrile is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure allows it to be a key component in the synthesis of various medicinal compounds, contributing to the creation of innovative treatments.
Used in Organic Synthesis:
In the field of organic synthesis, 7-Methoxyindole-3-acetonitrile serves as a building block for the preparation of various indole derivatives. Its presence in these syntheses can lead to the production of a wide range of chemical compounds with diverse applications.
Used in Biological Research:
7-Methoxyindole-3-acetonitrile is also used in biological research to study its potential biological activities and pharmacological properties. This research can provide valuable insights into the compound's effects on biological systems and may lead to the discovery of new therapeutic applications.

InChI:InChI=1/C11H10N2O/c1-14-10-4-2-3-9-8(5-6-12)7-13-11(9)10/h2-4,7,13H,5H2,1H3

Upstream product

• 773837-37-9 sodium cyanide 
• 109021-59-2 7-methoxy-1H-indole-3-carbaldehyde 
• 3189-22-8 7-methoxy-1H-indole 
• 46388-50-5 (7-methoxy-1H-indol-3-yl)-N,N-dimethylmethanamine 
• 7677-24-9 trimethylsilyl cyanide 

Relevant academic research and scientific papers

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI50 1.5 μM). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day.

New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations

Members of the kinesin superfamily are involved in key functions during intracellular transport and cell division. Their involvement in cell division makes certain kinesins potential targets for drug development in cancer chemotherapy. The two most advanc

SELECTIVE ANTI-CANCER COMPOUNDS

A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.

Synthesis of indolyl-3-acetonitrile derivatives and their inhibitory effects on nitric oxide and PGE2 productions in LPS-induced RAW 264.7 cells

Arvelexin is one of major constituents of Brassica rapa that exerts anti-inflammatory activities. Several indolyl-3-acetonitrile derivatives were synthesized as arvelexin analogs and evaluated for their abilities to inhibit NO and PGE2 productions in LPS-induced RAW 264.7 cells. Of the indolyl-3-acetonitriles synthesized, compound 2k, which possesses a hydroxyl group at C-7 position of the indole ring and an N-methyl substituent, more potently inhibited NO and PGE2 productions and was less cytotoxic than arvelexin on macrophage cells.